---
title: "TARE with Y90 microspheres shows survival benefit and low adverse event rate in intrahepatic cholangiocarcinoma"
date: "2024-05-08T09:34:22.000Z"
publishedDate: "8 mai 2024"
summary: "Etienne Garin (Centre Eugene Marquis, Rennes, France), presenting results from an ad-hoc interim analysis of the PROACTIF trial data, reported that “appropriately selected” patients who received transarterial radioembolization (TARE) with yttrium-90 (Y90) glass microspheres within a “personalised treatment plan” for primary and metastatic liver tumours—including intrahepatic cholangiocarcinoma (ICC)—achieved “long survival” and had a “low adverse [&#8230;] The post TARE with Y90 microspheres shows survival benefit and low adverse event rate in intrahepatic cholangiocarcinoma appeared first on Interventional News ."
importance: ""
sourceUrl: "https://interventionalnews.com/tare-with-y90-microspheres-shows-survival-benefit-and-low-adverse-event-rate-in-intrahepatic-cholangiocarcinoma/"
tags: ["France", "Actualité", "Interventional News — Latest"]
permalink: "/papers/2024-05-08-tare-with-y90-microspheres-shows-survival-benefit-and-low-adverse-event-rate-in-intrahepatic-cholangiocarcinoma"
imageUrl: "https://interventionalnews.com/wp-content/uploads/sites/13/2024/05/Image-20-scaled.jpeg"
imageCredit: "Image de l’article — droits possiblement réservés — https://interventionalnews.com/tare-with-y90-microspheres-shows-survival-benefit-and-low-adverse-event-rate-in-intrahepatic-cholangiocarcinoma/"
---

![TARE with Y90 microspheres shows survival benefit and low adverse event rate in intrahepatic cholangiocarcinoma](https://interventionalnews.com/wp-content/uploads/sites/13/2024/05/Image-20-scaled.jpeg)

*Crédit image : Image de l’article — droits possiblement réservés — https://interventionalnews.com/tare-with-y90-microspheres-shows-survival-benefit-and-low-adverse-event-rate-in-intrahepatic-cholangiocarcinoma/*

## L’essentiel

Etienne Garin (Centre Eugene Marquis, Rennes, France), presenting results from an ad-hoc interim analysis of the PROACTIF trial data, reported that “appropriately selected” patients who received transarterial radioembolization (TARE) with yttrium-90 (Y90) glass microspheres within a “personalised treatment plan” for primary and metastatic liver tumours—including intrahepatic cholangiocarcinoma (ICC)—achieved “long survival” and had a “low adverse [&#8230;] The post TARE with Y90 microspheres shows survival benefit and low adverse event rate in intrahepatic cholangiocarcinoma appeared first on Interventional News .

## Lien source

https://interventionalnews.com/tare-with-y90-microspheres-shows-survival-benefit-and-low-adverse-event-rate-in-intrahepatic-cholangiocarcinoma/
